Image 1_Immune-related RELT drives clear cell renal cell carcinoma progression through JAK/STAT signaling pathway activation.tiff

Image 1_Immune-related RELT drives clear cell renal cell carcinoma progression through JAK/STAT signaling pathway activation.tiff

Objective<p>The experiment aims to verify the function of Tumor Necrosis Factor Receptor Superfamily Member 19L (RELT) in clear cell renal cell carcinoma (ccRCC).</p>Methods<p>The relationship between differential expression of RELT in ccRCC and clinical prognosis was investigated...

Szczegółowa specyfikacja

Zapisane w:

Opis bibliograficzny
1. autor:	Yini Wang (410389) (author)
Kolejni autorzy:	Yingying Yang (1696258) (author), Tianqi Wang (4093009) (author), Xiaohong Ma (462719) (author), Jitao Wu (695795) (author)
Wydane:	2025
Hasła przedmiotowe:	Genetic Immunology ccRCC RELT tumor immune microenvironment JAK/STAT pathway T cell immunity
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy

Image 2_Immune-related RELT drives clear cell renal cell carcinoma progression through JAK/STAT signaling pathway activation.tiff
od: Yini Wang (410389)
Wydane: (2025)

Data Sheet 10_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
od: Huiping Fan (13921872)
Wydane: (2025)

Data Sheet 9_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
od: Huiping Fan (13921872)
Wydane: (2025)

Data Sheet 8_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
od: Huiping Fan (13921872)
Wydane: (2025)

Data Sheet 6_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
od: Huiping Fan (13921872)
Wydane: (2025)

Data Sheet 7_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
od: Huiping Fan (13921872)
Wydane: (2025)

Data Sheet 5_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
od: Huiping Fan (13921872)
Wydane: (2025)

Data Sheet 4_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
od: Huiping Fan (13921872)
Wydane: (2025)

Data Sheet 3_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
od: Huiping Fan (13921872)
Wydane: (2025)

Data Sheet 2_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
od: Huiping Fan (13921872)
Wydane: (2025)

Data Sheet 1_LL37-driven mast cell degranulation and inflammation in rosacea via TLR2/JAK2/STAT3 axis.zip
od: Huiping Fan (13921872)
Wydane: (2025)

Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers
od: Hasashi Hasumi (21471185)
Wydane: (2025)

Full list of metrics, indicators, and health-related outcomes used in PAICE rapid literature
od: Rachel Juel (11796266)
Wydane: (2025)

Table S19 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma
od: Zhenyuan Yu (14962287)
Wydane: (2025)

Table S20 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma
od: Zhenyuan Yu (14962287)
Wydane: (2025)

Table S8 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma
od: Zhenyuan Yu (14962287)
Wydane: (2025)

Table S9 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma
od: Zhenyuan Yu (14962287)
Wydane: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Wydane: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Wydane: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
od: Arianna Draghi (15126339)
Wydane: (2025)

Table S1 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
od: Guillaume Davidson (14964069)
Wydane: (2025)

Table S2 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
od: Guillaume Davidson (14964069)
Wydane: (2025)

Table S3 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
od: Guillaume Davidson (14964069)
Wydane: (2025)

Table S4 from Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma
od: Guillaume Davidson (14964069)
Wydane: (2025)

Drug retention rate of Janus kinase inhibitors in patients with rheumatoid arthritis: the KEIO-RA cohort study
od: Satoshi Takanashi (15221350)
Wydane: (2025)

Table S3, S5-S7, S10-S18, S21 from Integrative Single-Cell Analysis Reveals Transcriptional and Epigenetic Regulatory Features of Clear Cell Renal Cell Carcinoma
od: Zhenyuan Yu (14962287)
Wydane: (2025)

Figure 1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Wydane: (2025)

Figure 2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Wydane: (2025)

Figure 3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Wydane: (2025)

Figure 4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Wydane: (2025)

Figure 5 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Wydane: (2025)

Figure 6 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Wydane: (2025)

Figure 7 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Wydane: (2025)

Supplementary Table S1 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Wydane: (2025)

Supplementary Table S2 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Wydane: (2025)

Supplementary Table S3 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Wydane: (2025)

Supplementary Table S4 from Extracellular Vesicle Secretion by Leukemia Cells <i>In Vivo</i> Promotes CLL Progression by Hampering Antitumor T-cell Responses
od: Ernesto Gargiulo (15134961)
Wydane: (2025)

Supplementary Tables TS1-23 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
od: Xiaofan Lu (15049989)
Wydane: (2025)

Supplementary Table S1 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
od: Laura E. Stevens (14961009)
Wydane: (2025)

Supplementary Table S2 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
od: Laura E. Stevens (14961009)
Wydane: (2025)

Cannot write session to /tmp/vufind_sessions/sess_8kcchj6mjg51n1tknp1n2guk27